Literature DB >> 2912326

The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma.

T Haahtela1, K Alanko, A Muittari, A Lahdensuo, K Sahlström, V Vilkka.   

Abstract

We studied the clinical effect of a combination aerosol containing salbutamol and beclomethasone dipropionate in comparison to doubling the standard dose of salbutamol from an inhaler. Fifty-seven patients completed the double-blind, crossover study. They were treated with either an aerosol of 100 micrograms beclomethasone dipropionate and 200 micrograms salbutamol or 400 micrograms salbutamol alone. Both regimens were administered four times a day for 4 weeks. The patients showed significant improvement in FEV1, PEFR, and symptom scores after treatment with beclomethasone dipropionate and salbutamol compared with pre-trial values and with treatment with double the dose of salbutamol. The patients demonstrated a clear preference for treatment with the combination of beclomethasone dipropionate and salbutamol. Regular treatment with beclomethasone dipropionate in addition to salbutamol as a combination inhaler provides much better control of asthma than merely increasing the dose of salbutamol in those patients poorly controlled on standard doses of inhaled bronchodilators.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912326

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  4 in total

Review 1.  Interactions between corticosteroids and beta agonists.

Authors:  D R Taylor; R J Hancox
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis.

Authors:  P M van Grunsven; C P van Schayck; J Molema; R P Akkermans; C van Weel
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

3.  It is time to end our love affair with short-acting β2-agonists in asthma.

Authors:  Michael G Crooks; Shoaib Faruqi
Journal:  ERJ Open Res       Date:  2022-10-17

Review 4.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.